Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection

Eur J Clin Invest. 2020 Oct;50(10):e13366. doi: 10.1111/eci.13366. Epub 2020 Aug 16.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Betacoronavirus
  • Biphenyl Compounds / therapeutic use*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Crotonates / therapeutic use
  • Dihydroorotate Dehydrogenase
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Hydroxybutyrates
  • Leflunomide / therapeutic use*
  • Nitriles
  • Oxidoreductases Acting on CH-CH Group Donors / antagonists & inhibitors*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pyrimidines / biosynthesis
  • SARS-CoV-2
  • Toluidines / therapeutic use
  • Virus Replication

Substances

  • Antiviral Agents
  • Biphenyl Compounds
  • Crotonates
  • Dihydroorotate Dehydrogenase
  • Enzyme Inhibitors
  • Hydroxybutyrates
  • Nitriles
  • Pyrimidines
  • Toluidines
  • teriflunomide
  • brequinar
  • Oxidoreductases Acting on CH-CH Group Donors
  • Leflunomide